Benzinga | Jan 5, 2021 07:29AM EST

Credit Suisse Initiates Coverage On AbCellera Biologics with Outperform Rating

Credit Suisse analyst Tiago Fauth initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Outperform rating.